firsekibart

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
firsekibart

GtoPdb Ligand ID: 14399

Synonyms: Jin Beixin® (China)

firsekibart is an approved drug

Compound class: Antibody

Comment: Firsekibart (previously genakumab) is an IgG4λ monoclonal antibody that targets interleukin-1β (IL-1β). It was developed for anti-inflammatory potential. Based on peptide sequence matches for the heavy and light variable regions of firsekibart, this appears to be antibody 048Ab-4 (H2L6) in patent CN106928354A [2].

References
1. Jing R, Zhi X, Shao L. (2026) Approvals by the China NMPA in 2025. Nat Rev Drug Discov, [Epub ahead of print]. [PMID:41688808]
2. Xiao F, Tao W, Lei J, Suofo Q, Yuheng C. (2017) The monoclonal antibodies of anti-IL 1β and its application. Patent number: CN106928354A. Assignee: JINSAI DRUG CO Ltd CHANGCHUN Changchun Genescience Pharmaceutical Co Ltd. Priority date: 25/04/2017. Publication date: 07/07/2017.
3. Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, Yu J, Li R, Li R, Qian L et al.. (2025) Firsekibart in acute gouty arthritis. J Transl Med, 23 (1): 91. [PMID:39838494]
4. Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, Yu J, Li R, Li R, Qian L et al.. (2025) Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial. Innovation (Camb), 6 (8): 101015. [PMID:40814346]
5. Yu Y, Xue Y, Hu J, Zhang N, Li R, Guo H, Qian L, Gou W, Yang J, Mao L et al.. (2025) Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled Trial. ACR Open Rheumatol, 7 (11): e70111. [PMID:41200857]

References

1. Jing R, Zhi X, Shao L. (2026)
Approvals by the China NMPA in 2025.
Nat Rev Drug Discov, [Epub ahead of print]. [PMID:41688808]

2. Xiao F, Tao W, Lei J, Suofo Q, Yuheng C. (2017)
The monoclonal antibodies of anti-IL 1β and its application.
Patent number: CN106928354A. Assignee: JINSAI DRUG CO Ltd CHANGCHUN Changchun Genescience Pharmaceutical Co Ltd. Priority date: 25/04/2017. Publication date: 07/07/2017.

3. Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, Yu J, Li R, Li R, Qian L et al.. (2025)
Firsekibart in acute gouty arthritis.
J Transl Med, 23 (1): 91. [PMID:39838494]

4. Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, Yu J, Li R, Li R, Qian L et al.. (2025)
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial.
Innovation (Camb), 6 (8): 101015. [PMID:40814346]

5. Yu Y, Xue Y, Hu J, Zhang N, Li R, Guo H, Qian L, Gou W, Yang J, Mao L et al.. (2025)
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled Trial.
ACR Open Rheumatol, 7 (11): e70111. [PMID:41200857]